Pan-JAK Inhibitors (Theravance/Pfizer)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePan-JAK Inhibitors (Theravance/Pfizer)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitors
TargetsJanus kinase
Therapy Area/IndicationsSkin Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTheravance Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheravance Biopharma IncPfizer Inc
Inactive CompaniesN/A
Active IndicationsSkin Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A